Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

brigatinib 2ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × ALK-positive Advanced NSCLC × Clear all
NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed
103 enrolled 23 charts
Thoracic

ALK-positive Advanced NSCLC

NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study

Fujian Medical University Union Hospital

Phase 4 Not yet recruiting
30 enrolled
Thoracic

ALK-positive Advanced NSCLC

NCT03410108 2024-05-08

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Takeda

Phase 2 Completed
104 enrolled 22 charts
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡